共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 2020年老年心血管急重症研究进展显示文摘2020年必定是史上最不平凡的一年,中国乃至全球都经历着新冠病毒(COVID-19)感染疫情的肆虐,全球近1亿人被感染,近200万人死亡,人们的日常工作与生活等都受到了不同程度的影响,医疗机构与医疗服务更是不堪其甚,即使如此,明天的太阳依旧会照常升起来。值此岁末年初,简单回顾老年心血管急重症进展之一二,供同道分享。 | 张新超 陈曦 | 2021 | 中华急诊医学杂志2021，30，2： | 3 |
| 2 | Usefulness of Impella support in different clinical settings in cardiogenic shock显示文摘BACKGROUND The Impella pump has emerged as a promising tool in patients with cardiogenic shock(CS).Despite its attractive properties,there are scarce data on the specific clinical setting and the potential role of Impella devices in CS patients from routine clinical practice.METHODS This is an observational,retrospective,single center,cohort study.All consecutive patients with diagnosis of CS and undergoing support with Impella 2.5?,Impella CP?or Impella 5.0?from April 2015 to December 2020 were included.Baseline characteristics,management and outcomes were assessed according to CS severity,age and cause of CS.Main outcome measured was in-hospital mortality.RESULTS A total of 50 patients were included(median age:59.3±10 years).The most common cause of CS was acute coronary syndrome(ACS)(68%),followed by decompensation of previous cardiomyopathy(22%).A total of 13 patients(26%)had profound CS.Most patients(54%)improved pulmonary congestion at 48 h after Impella support.A total of 19 patients(38%)presented significant bleeding.In-hospital mortality was 42%.Among patients with profound CS(n=13),five patients were previously supported with venoarterial extracorporeal membrane oxygenation.A total of eight patients(61.5%)died during the admission,and no patient achieved ventricular recovery.Older patients(≥67 years,n=10)had more comorbidities and the highest mortality(70%).Among patients with ACS(n=34),35.3%of patients had profound CS;and in most cases(52.9%),Impella support was performed as a bridge to recovery.In contrast,only one patient from the decompensated cardiomyopathy group(n=11)presented with profound CS.In 90.9%of these cases,Impella support was used as a bridge to cardiac transplantation.There were no cases of death.CONCLUSIONS In this cohort of real-life CS patients,Impella devices were used in different settings,with different clinical profiles and management.Despite a significant rate of complications,mortality was acceptable and lower than those observed in other series. | María Isabel Barrionuevo-Sánchez Albert Ariza-Solé Daniel Ortiz-Berbel JoséGonzález-Costello Joan Antoni Gómez-Hospital Victòria Lorente Oriol Alegre Isaac Llaó JoséCarlos Sánchez-Salado Josep Gómez-Lara Arnau Blasco-Lucas Josep Comin-Colet | 2022 | Journal of Geriatric Cardiology2022，19，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员